Peapod Lane Capital LLC Invests $1.73 Million in OraSure Technologies, Inc. (NASDAQ:OSUR)

Peapod Lane Capital LLC acquired a new stake in OraSure Technologies, Inc. (NASDAQ:OSUR) in the 4th quarter, according to its most recent filing with the SEC. The fund acquired 479,323 shares of the medical instruments supplier’s stock, valued at approximately $1,730,000. OraSure Technologies accounts for about 1.7% of Peapod Lane Capital LLC’s investment portfolio, making the stock its 24th biggest holding.

Other large investors have also bought and sold shares of the company. Empowered Funds LLC lifted its stake in OraSure Technologies by 5.1% in the fourth quarter. Empowered Funds LLC now owns 377,906 shares of the medical instruments supplier’s stock valued at $1,364,000 after buying an additional 18,487 shares in the last quarter. Exchange Traded Concepts LLC acquired a new stake in shares of OraSure Technologies in the 4th quarter valued at about $287,000. SG Americas Securities LLC bought a new stake in shares of OraSure Technologies in the fourth quarter valued at about $205,000. Marquette Asset Management LLC boosted its position in shares of OraSure Technologies by 44.4% during the fourth quarter. Marquette Asset Management LLC now owns 69,345 shares of the medical instruments supplier’s stock worth $250,000 after buying an additional 21,327 shares during the period. Finally, JPMorgan Chase & Co. boosted its position in shares of OraSure Technologies by 5.8% during the third quarter. JPMorgan Chase & Co. now owns 847,933 shares of the medical instruments supplier’s stock worth $3,621,000 after buying an additional 46,216 shares during the period. 93.50% of the stock is owned by institutional investors.

OraSure Technologies Trading Down 2.1 %

Shares of OSUR opened at $3.74 on Thursday. The stock has a market capitalization of $278.97 million, a price-to-earnings ratio of 24.93 and a beta of 0.05. The firm has a fifty day simple moving average of $3.81 and a 200 day simple moving average of $4.05. OraSure Technologies, Inc. has a 12 month low of $3.52 and a 12 month high of $8.04.

Wall Street Analysts Forecast Growth

Separately, StockNews.com lowered OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Thursday.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.